<br>        Inclusion Criteria:<br><br>          -  Healthy male and female subjects age 18 to 55 years of age included, and in good<br>             health<br><br>          -  At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and<br>             pulse rate) will be assessed after the subject has rested for at least five (5)<br>             minutes, and again when required after three (3) minutes in the standing position.<br>             Vital signs should be within the normal ranges<br><br>          -  Body mass index (BMI) within the range of 18 to 27 and weigh at least 50 kg<br><br>          -  Female subjects must have undergone hysterectomy, or must be postmenopausal.<br><br>        Exclusion Criteria:<br><br>          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,<br>             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or<br>             psychiatric disease<br><br>          -  History of malignancy of any organ system, treated or untreated, within the past 5<br>             years whether or not there is evidence of local recurrence or metastases, with the<br>             exception of localized basal cell carcinoma of the skin<br><br>          -  Receiving monoamine oxidase (MAO) inhibitors within 28 days prior to the first dose<br><br>          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result<br><br>          -  History of clinically significant drug allergy or history of atopic allergy (asthma,<br>             urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or<br>             drugs similar to the study drug.<br><br>          -  Significant illness within two weeks prior to dosing<br><br>          -  Subjects who, through completion of the study, would have donated in excess of: 500<br>             mL of blood in 14 days; 1500 mL of blood in 180 days; 2500 mL of blood in 1 year.<br><br>          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western<br>             blot) test result.<br><br>          -  History of drug or alcohol abuse within the 12 months prior to dosing or evidence of<br>             such abuse as indicated by the laboratory assays conducted during the screening or<br>             baseline evaluations.<br><br>          -  Women of child bearing potential ( WOCBP)<br><br>          -  History or presence of glaucoma or any suspicious undiagnosed skin lesions<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>